查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1605923

转移性肺腺癌治疗市场、规模、占有率、趋势、行业分析报告：按治疗、按最终用户、按地区 - 2025-2034 年市场预测

Metastatic Lung Adenocarcinoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2034 年，全球转移性肺腺癌治疗市场规模预计将达到 141.7 亿美元。该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

标靶治疗和免疫疗法的进步显着改善了患者的治疗效果、肺癌盛行率的增加以及对个人化医疗的需求不断增长，推动了转移性肺腺癌治疗市场的成长。

专门针对特定基因突变（例如 EGFR 和 ALK）的新疗法的开发将在未来几年提供市场机会。趋势表明，人们越来越关注联合疗法和生物标记驱动的方法，以提高治疗效果。总体而言，随着製药公司大力投资研发以满足新兴市场患者群体不断增长的需求，该市场预计将扩大。

转移性肺腺癌治疗市场报告亮点

在治疗方面，免疫疗法由于持久的反应和提高的生存率而在市场上占据主导地位。标靶治疗领域也出现了强劲成长，特别是对于已识别出 EGFR 等基因突变的患者。

从最终用户来看，由于拥有先进的治疗方案和综合护理设施，医院部门仍然是转移性肺腺癌治疗市场的最大股东。为了满足对强化和个人化癌症治疗日益增长的需求，专科诊所部门正在快速成长。

由于大型製药公司和先进的医疗基础设施的存在，北美在全球转移性肺腺癌治疗市场中占据主导地位。在癌症发生率上升和医疗保健投资增加的推动下，亚太地区是成长最快的市场。

阿斯特捷利康、罗氏、默克公司、百时美施贵宝、辉瑞公司、诺华公司、礼来公司、安进公司、赛诺菲公司、勃林格殷格翰公司、武田製药公司、强生公司、艾伯维公司、拜耳公司和葛兰素史克公司都是转移性的是肺腺癌治疗市场的主要参与者。

目录

第1章简介

第 2 章执行摘要

第3章研究方法

第 4 章转移性肺腺癌治疗的全球市场洞察

  • 市场快照
  • 转移性肺腺癌治疗市场动态
    • 促进因素和机会
      • 越来越重视标靶治疗
      • 免疫疗法的进展
    • 抑制因素和挑战
      • 存活率低
  • PESTEL 分析
  • 转移性肺腺癌治疗市场的趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第5章转移性肺腺癌治疗的全球市场：依治疗分类

  • 主要发现
  • 简介
  • 化疗
  • 标靶治疗
  • 免疫治疗
  • 治疗
  • 其他

第 6 章全球转移性肺腺癌治疗市场：依最终使用者划分

  • 主要发现
  • 简介
  • 医院
  • 专科诊所
  • 其他

第7章全球转移性肺腺癌治疗市场：依地区

  • 主要发现
  • 简介
    • 转移性肺腺癌治疗市场评估：地区，2020-2034 年
  • 北美
    • 北美：依治疗方式划分，2020-2034 年
    • 北美：依最终使用者划分，2020-2034 年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：依处理方式，2020-2034 年
    • 欧洲：依最终使用者划分，2020-2034 年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 欧洲其他地区
  • 亚太地区
    • 亚太地区：依处理方式，2020-2034 年
    • 亚太地区：依最终使用者划分，2020-2034 年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳大利亚
    • 其他亚太地区
  • 中东/非洲
    • 中东和非洲：依治疗方式划分，2020 年至 2034 年
    • 中东和非洲：按最终用户划分，2020-2034 年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲：依处理方式划分，2020-2034 年
    • 拉丁美洲：依最终使用者划分，2020-2034 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区

第8章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第9章公司简介

  • AstraZeneca
  • Roche
  • Merck & Co
  • Bristol-Myers Squibb
  • Pfizer
  • Novartis
  • Eli Lilly and Company
  • Amgen
  • Sanofi
  • Boehringer Ingelheim
  • Takeda Pharmaceutical Company
Product Code: PM5255

The global metastatic lung adenocarcinoma treatment market size is expected to reach USD 14.17 billion by 2034, according to a new study by Polaris Market Research. The report "Metastatic Lung Adenocarcinoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The metastatic lung adenocarcinoma treatment market growth can be attributed to advancements in targeted therapies and immunotherapies that are significantly improving patient outcomes, increasing prevalence of lung cancer, and the rising demand for personalized medicine.

The development of novel treatment options, particularly those targeting specific genetic mutations such as EGFR and ALK, would offer opportunities for the market in the coming years. Trends indicate a growing focus on combination therapies and biomarker-driven approaches to enhance treatment efficacy. Overall, the market is expected to expand as pharmaceutical companies invest heavily in research and development to meet the evolving needs of this patient population.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

Based on treatment, the immunotherapy segment dominates the market due to its ability to provide durable responses and improved survival rates. The targeted therapy segment is also seeing significant growth, particularly in patients with identifiable genetic mutations such as EGFR.

In terms of end users, the hospital segment remains the largest shareholder in the metastatic lung adenocarcinoma treatment market, driven by the availability of advanced treatment options and comprehensive care facilities. The specialty clinics segment is growing rapidly, catering to the increasing demand for focused and personalized cancer treatment.

North America dominates the global metastatic lung adenocarcinoma treatment market, attributed to the presence of major pharmaceutical companies and advanced healthcare infrastructure. Asia Pacific is the fastest-growing market, propelled by rising cancer incidence rates and increasing healthcare investments.

AstraZeneca, Roche, Merck & Co., Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly and Company, Amgen, Sanofi, Boehringer Ingelheim, Takeda Pharmaceutical Company, Johnson & Johnson, AbbVie, Bayer, and GlaxoSmithKline are among the key players in the metastatic lung adenocarcinoma treatment market.

Polaris Market Research has segmented the metastatic lung adenocarcinoma treatment market report on the basis of treatment, end user, and region:

By Treatment Outlook (Revenue - USD Billion, 2020-2034)

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Others

By End User Outlook (Revenue - USD Billion, 2020-2034)

  • Hospitals
  • Specialty Clinics
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Metastatic Lung Adenocarcinoma Treatment Market Insights

  • 4.1. Metastatic Lung Adenocarcinoma Treatment Market - Market Snapshot
  • 4.2. Metastatic Lung Adenocarcinoma Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased Focus on Targeted Therapies
      • 4.2.1.2. Advancements in Immunotherapy
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Low Survival Rates
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Metastatic Lung Adenocarcinoma Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 5.4. Targeted Therapy
    • 5.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 5.5. Immunotherapy
    • 5.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 5.6. Therapy
    • 5.6.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Hospitals, by Region, 2020-2034 (USD Billion)
  • 6.4. Specialty Clinics
    • 6.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Specialty Clinics, by Region, 2020-2034 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Metastatic Lung Adenocarcinoma Treatment Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Metastatic Lung Adenocarcinoma Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Metastatic Lung Adenocarcinoma Treatment Market - North America
    • 7.3.1. North America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.3.2. North America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.3.3. Metastatic Lung Adenocarcinoma Treatment Market - U.S.
      • 7.3.3.1. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.3.4. Metastatic Lung Adenocarcinoma Treatment Market - Canada
      • 7.3.4.1. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4. Metastatic Lung Adenocarcinoma Treatment Market - Europe
    • 7.4.1. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.3. Metastatic Lung Adenocarcinoma Treatment Market - UK
      • 7.4.3.1. UK: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.4. Metastatic Lung Adenocarcinoma Treatment Market - France
      • 7.4.4.1. France: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.5. Metastatic Lung Adenocarcinoma Treatment Market - Germany
      • 7.4.5.1. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.6. Metastatic Lung Adenocarcinoma Treatment Market - Italy
      • 7.4.6.1. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.7. Metastatic Lung Adenocarcinoma Treatment Market - Spain
      • 7.4.7.1. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.8. Metastatic Lung Adenocarcinoma Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.9. Metastatic Lung Adenocarcinoma Treatment Market - Russia
      • 7.4.9.1. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5. Metastatic Lung Adenocarcinoma Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.3. Metastatic Lung Adenocarcinoma Treatment Market - China
      • 7.5.3.1. China: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.4. Metastatic Lung Adenocarcinoma Treatment Market - India
      • 7.5.4.1. India: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.5. Metastatic Lung Adenocarcinoma Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.6. Metastatic Lung Adenocarcinoma Treatment Market - Japan
      • 7.5.6.1. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.7. Metastatic Lung Adenocarcinoma Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.8. Metastatic Lung Adenocarcinoma Treatment Market - South Korea
      • 7.5.8.1. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.9. Metastatic Lung Adenocarcinoma Treatment Market - Australia
      • 7.5.9.1. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6. Metastatic Lung Adenocarcinoma Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.3. Metastatic Lung Adenocarcinoma Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.4. Metastatic Lung Adenocarcinoma Treatment Market - UAE
      • 7.6.4.1. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.5. Metastatic Lung Adenocarcinoma Treatment Market - Israel
      • 7.6.5.1. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.6. Metastatic Lung Adenocarcinoma Treatment Market - South Africa
      • 7.6.6.1. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.7. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.7. Metastatic Lung Adenocarcinoma Treatment Market - Latin America
    • 7.7.1. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.3. Metastatic Lung Adenocarcinoma Treatment Market - Mexico
      • 7.7.3.1. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.4. Metastatic Lung Adenocarcinoma Treatment Market - Brazil
      • 7.7.4.1. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.5. Metastatic Lung Adenocarcinoma Treatment Market - Argentina
      • 7.7.5.1. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.6. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AstraZeneca
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Roche
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Merck & Co
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bristol-Myers Squibb
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Pfizer
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Novartis
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Eli Lilly and Company
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Amgen
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Sanofi
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Boehringer Ingelheim
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Takeda Pharmaceutical Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development

List of Tables:

  • Table 1 Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 2 Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 3 North America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 4 North America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 5 U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 6 U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 7 Canada: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 8 Canada: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 9 Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 10 Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 11 UK: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 12 UK: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 13 France: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 14 France: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 15 Germany: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 16 Germany: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 17 Italy: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 18 Italy: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 19 Spain: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 20 Spain: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 23 Russia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 24 Russia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 29 China: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 30 China: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 31 India: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 32 India: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 35 Japan: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 36 Japan: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 39 South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 40 South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 41 Australia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 42 Australia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 49 UAE: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 50 UAE: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 51 Israel: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 52 Israel: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 53 South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 54 South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 57 Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 58 Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 59 Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 60 Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 61 Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 62 Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 63 Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 64 Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • List of Figures:
  • Figure 1. Global Metastatic Lung Adenocarcinoma Treatment Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End User
  • Figure 9. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2024 & 2034 (USD Billion)